Shipping services continue despite COVID-19 outbreak ! Click here to view COVID-19 related products

JNJ-26854165 (Serdemetan)

For research use only.

Catalog No.S1172

11 publications

JNJ-26854165 (Serdemetan) Chemical Structure

CAS No. 881202-45-5

JNJ-26854165 (Serdemetan) acts as a HDM2 ubiquitin ligase antagonist and also induces early apoptosis in p53 wild-type cells, inhibits cellular proliferation followed by delayed apoptosis in the absence of functional p53. Phase 1.

Size Price Stock Quantity  
10mM (1mL in DMSO) EUR 137 In stock
EUR 108 In stock
EUR 363 In stock
EUR 953 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's JNJ-26854165 (Serdemetan) has been cited by 11 publications

6 Customer Reviews

  • Mol Pharmacol 2014 85(3), 408-19. JNJ-26854165 (Serdemetan) purchased from Selleck.

    Sci Rep 2014 4, 4663. JNJ-26854165 (Serdemetan) purchased from Selleck.

  • Sci Rep 2014 4, 4663. JNJ-26854165 (Serdemetan) purchased from Selleck.

    Sci Rep 2014 4, 4663. JNJ-26854165 (Serdemetan) purchased from Selleck.

  • J Nat Med 2013 10.1007/s11418-014-0825-0. JNJ-26854165 (Serdemetan) purchased from Selleck.

    Curr Protoc Chem Biol 2013 5(3), 195-212. JNJ-26854165 (Serdemetan) purchased from Selleck.

Purity & Quality Control

Choose Selective p53 Inhibitors

Biological Activity

Description JNJ-26854165 (Serdemetan) acts as a HDM2 ubiquitin ligase antagonist and also induces early apoptosis in p53 wild-type cells, inhibits cellular proliferation followed by delayed apoptosis in the absence of functional p53. Phase 1.
Targets
p53 [1]
(Cell-free assay)
HDM2 [1]
(Cell-free assay)
Mdm2 [2]
(Cell-free assay)
In vitro

JNJ 26854165 is a novel tryptamine derivative which activates p53 and acts as a HDM2 ubiquitin ligase antagonist. JNJ 26854165 inhibits cell growth and induces apoptosis in leukemia cell lines with IC50 values of 0.24, 0.33, 0.32 and 0.44 μM at 72 hours for OCI-AML-3, MOLM-13, NALM-6 and REH cells, respectively. In addition, JNJ 26854165 accelerates proteasome-mediated degradation of p21 and antagonizes the transcriptional induction of p21 by p53. It also induces S-phase delay and upregulates E2F1 expression in p53 mutant cells, resulting in preferential apoptosis of S-phase cells. [1] JNJ 26854165 is an oral Mdm2 inhibitor which can inhibit the interaction of Mdm2-p53 complex with the proteasome and increase p53 levels by binding to RING domain of Mdm2. [2] A recent study shows that JNJ 26854165 inhibits clonogenic survival in four human cancer cell lines: H460, A549, p53-WT-HCT116, and p53-null-HCT116. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
KU-19-19 cell M{\lb2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NGXKfJFKdmirYnn0bY9vKG:oIHj1cYFvKEuXLUG5MVE6KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC57M{KzOkDPxE1? NEXYfoRUSU6JRWK=
H4 cell NIXVU5dIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MkX0TY5pcWKrdHnvckBw\iCqdX3hckBJPCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTFwME[3NFch|ryP M4XXO3NCVkeHUh?=
KGN cell MV3Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NEnPdGlKdmirYnn0bY9vKG:oIHj1cYFvKEuJTjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGuOlIxPSEQvF2= NWHrSWxDW0GQR1XS
786-0 cell NX7pdlZGT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MVHJcohq[mm2aX;uJI9nKGi3bXHuJFc5Pi1yIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MT63Nlk5QSEQvF2= NHOyRmRUSU6JRWK=
769-P cell NIjpUIhIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NFXr[4tKdmirYnn0bY9vKG:oIHj1cYFvKDd4OT3QJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU45OjJ{NDFOwG0> M{XoVHNCVkeHUh?=
K5 cell NHzSTpNIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NHTvNGJKdmirYnn0bY9vKG:oIHj1cYFvKEt3IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Mj6wNVYzPCEQvF2= NH3JXHJUSU6JRWK=
MLMA cell M{PpWmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NUXNcmVlUW6qaXLpeIlwdiCxZjDoeY1idiCNT2PDMVIh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0zNjB|MkG3JO69VQ>? NGW5ZpJUSU6JRWK=
MLMA cell MX7Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MXHJcohq[mm2aX;uJI9nKGi3bXHuJG1NVUFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1{LkK4O|A{KM7:TR?= MVfTRW5ITVJ?
EW-7 cell MWDHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MmnOTY5pcWKrdHnvckBw\iCqdX3hckBGXy15IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Mj6zNlY6PSEQvF2= NF3EWpNUSU6JRWK=
SW1088 cell NEjVeJRIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NYHWfFJqUW6qaXLpeIlwdiCxZjDoeY1idiCVV{GwPFgh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0zNjhyNkWxJO69VQ>? NWfhdmZHW0GQR1XS
MC-IXC cell MUDHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NXrnfVR6UW6qaXLpeIlwdiCxZjDoeY1idiCPQz3JXGMh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0zNjh5N{myJO69VQ>? NEfU[5hUSU6JRWK=
NCI-H2052 cell MVHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M3rM[GlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLViyNFUzKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Oy5yOEG1O{DPxE1? M1TkXHNCVkeHUh?=
IGR-1 cell MVPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NV3qVldHUW6qaXLpeIlwdiCxZjDoeY1idiCLR2KtNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVMvOTJyMkig{txO MVzTRW5ITVJ?
DSH1 cell NUPlU|dJT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= Ml[1TY5pcWKrdHnvckBw\iCqdX3hckBFW0hzIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Mz6yOFI6PiEQvF2= NILzXmVUSU6JRWK=
PA-1 cell MoezS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MkDaTY5pcWKrdHnvckBw\iCqdX3hckBRSS1zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Mz6zNFA2Qc7:TR?= MWrTRW5ITVJ?
SK-MEL-3 cell M3vrO2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MkTaTY5pcWKrdHnvckBw\iCqdX3hckBUUy2PRVytN{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVMvOzF{MEeg{txO NH;KXppUSU6JRWK=
SW900 cell NFP1cHhIem:5dHigbY5pcWKrdHnvckBie3OjeR?= Moe1TY5pcWKrdHnvckBw\iCqdX3hckBUXzlyMDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUOuOFgzPTVizszN MkXKV2FPT0WU
CAKI-1 cell MXHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? Mki4TY5pcWKrdHnvckBw\iCqdX3hckBESUuLLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zMlUzPzN6IN88US=> MmTrV2FPT0WU
ES1 cell NH7PelZIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NHP5d|FKdmirYnn0bY9vKG:oIHj1cYFvKEWVMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUOuOVI5QTdizszN NWrJW5BLW0GQR1XS
SK-N-DZ cell MUTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NFLTSnBKdmirYnn0bY9vKG:oIHj1cYFvKFONLV6tSHoh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0{NjZ{NUm1JO69VQ>? NY\UVmZVW0GQR1XS
RH-1 cell M1njVGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MoHKTY5pcWKrdHnvckBw\iCqdX3hckBTUC1zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Mz62PFQ3OyEQvF2= MVnTRW5ITVJ?
ES8 cell MnXjS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NXLLc3hrUW6qaXLpeIlwdiCxZjDoeY1idiCHU{igZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zMlY6PzB{IN88US=> NYLrfXBYW0GQR1XS
NEC8 cell NFG2NYdIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MYTJcohq[mm2aX;uJI9nKGi3bXHuJG5GSzhiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1|Lke2PVgzKM7:TR?= NHPte21USU6JRWK=
LNCaP-Clone-FGC cell NVPJNFIzT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M{XJb2lvcGmkaYTpc44hd2ZiaIXtZY4hVE6FYWCtR4xwdmVvRlfDJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9N{45OzV|NjFOwG0> NUfkOJdbW0GQR1XS
HCE-4 cell NX;6cmdTT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MVnJcohq[mm2aX;uJI9nKGi3bXHuJGhETS12IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Mz65PFA4KM7:TR?= MlHOV2FPT0WU
U-118-MG cell NITFfHdIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MmfuTY5pcWKrdHnvckBw\iCqdX3hckBWNTFzOD3NS{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVQvODFyNk[g{txO NVuxcGQzW0GQR1XS
GI-ME-N cell NXn5e4tkT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NXfNSYtkUW6qaXLpeIlwdiCxZjDoeY1idiCJST3NSU1PKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PC5yOEe5OkDPxE1? M1zBfHNCVkeHUh?=
LB1047-RCC cell MnX3S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MlnETY5pcWKrdHnvckBw\iCqdX3hckBNSjFyNEetVmNEKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PC5zNkG0N{DPxE1? NULUZWNrW0GQR1XS
HT-1080 cell NEe5d41Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= NY\LRVhLUW6qaXLpeIlwdiCxZjDoeY1idiCKVD2xNFgxKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PC5zOUmyNUDPxE1? MUjTRW5ITVJ?
NB69 cell NIjZdVhIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M{XndWlvcGmkaYTpc44hd2ZiaIXtZY4hVkJ4OTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUSuN|UxPDdizszN MlnKV2FPT0WU
NCI-H1693 cell NFO5TpZIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NGjmTHZKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3INVY6OyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTRwNES4PVUh|ryP M3\ENHNCVkeHUh?=
HSC-3 cell MVXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MmTQTY5pcWKrdHnvckBw\iCqdX3hckBJW0NvMzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUSuOFk6OzNizszN M3jkWnNCVkeHUh?=
MDA-MB-231 cell M1X1PGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NH\kWYpKdmirYnn0bY9vKG:oIHj1cYFvKE2GQT3NRk0zOzFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD12LkW1PFk6KM7:TR?= M1LjfHNCVkeHUh?=
HOS cell MYPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MWjJcohq[mm2aX;uJI9nKGi3bXHuJGhQWyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTRwN{i2N{DPxE1? Ml7OV2FPT0WU
BT-549 cell M4nLemdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NVvWclQzUW6qaXLpeIlwdiCxZjDoeY1idiCEVD21OFkh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF01Njd6OEeg{txO NYnmRmhHW0GQR1XS
NB17 cell M{O2Nmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NXjj[JF1UW6qaXLpeIlwdiCxZjDoeY1idiCQQkG3JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OE44QDl5NjFOwG0> MmnrV2FPT0WU
5637 cell MoHlS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M2D3emlvcGmkaYTpc44hd2ZiaIXtZY4hPTZ|NzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUSuO|k3PTJizszN MoHyV2FPT0WU
OVCAR-8 cell MUTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MXvJcohq[mm2aX;uJI9nKGi3bXHuJG9XS0GULUigZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME20MlkzPDN4IN88US=> MorrV2FPT0WU
G-402 cell NVrRSoxrT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MV3Jcohq[mm2aX;uJI9nKGi3bXHuJGcuPDB{IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;ND65N|A{PSEQvF2= NVW3bYp1W0GQR1XS
BB30-HNC cell NEDoS5JIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MXvJcohq[mm2aX;uJI9nKGi3bXHuJGJDOzBvSF7DJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OU4xPzJzODFOwG0> MV;TRW5ITVJ?
HCC1806 cell MVfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MXPJcohq[mm2aX;uJI9nKGi3bXHuJGhESzF6ME[gZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21MlA5OzN7IN88US=> M1HKeXNCVkeHUh?=
COLO-800 cell MoqzS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M4j4fmlvcGmkaYTpc44hd2ZiaIXtZY4hS0:OTz24NFAh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF02NjF{NkSg{txO MVvTRW5ITVJ?
FADU cell MVHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NX7mVllIUW6qaXLpeIlwdiCxZjDoeY1idiCIQVTVJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OU4{PjV3NzFOwG0> NGDjTpVUSU6JRWK=
NCI-H1651 cell M4DycGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MlzUTY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEG2OVEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF02NjN7NEC5JO69VQ>? MnPsV2FPT0WU
AGS cell NGexflNIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NHXhR3NKdmirYnn0bY9vKG:oIHj1cYFvKEGJUzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUWuOFc4OTFizszN NHfGUmZUSU6JRWK=
CHP-212 cell NV7MSldET3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M2TOSWlvcGmkaYTpc44hd2ZiaIXtZY4hS0iSLUKxNkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVUvOzl2MEmg{txO NXPFNZpwW0GQR1XS
YAPC cell MnKxS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NIGxU49KdmirYnn0bY9vKG:oIHj1cYFvKFmDUFOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21MlQ4PzFzIN88US=> NVrPc2RWW0GQR1XS
GOTO cell MoqyS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M4npSWlvcGmkaYTpc44hd2ZiaIXtZY4hT0:WTzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUWuOFk2PzZizszN NI[2NHdUSU6JRWK=
KYSE-510 cell MmSxS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MYnJcohq[mm2aX;uJI9nKGi3bXHuJGt[W0VvNUGwJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OU42OTFizszN MWLTRW5ITVJ?
NCI-H2342 cell M2P1dWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M3zTZmlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLViyN|QzKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PS53M{K3PEDPxE1? M2jJUHNCVkeHUh?=
BFTC-905 cell M4Lv[2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MYHJcohq[mm2aX;uJI9nKGi3bXHuJGJHXENvOUC1JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OU43Ojh|NTFOwG0> NVjYcpBMW0GQR1XS
EW-16 cell NYftT4d7T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= Mn\UTY5pcWKrdHnvckBw\iCqdX3hckBGXy1zNjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUWuO|IxQTNizszN MUfTRW5ITVJ?
SK-MEL-30 cell NFWyWWJIem:5dHigbY5pcWKrdHnvckBie3OjeR?= Mn\wTY5pcWKrdHnvckBw\iCqdX3hckBUUy2PRVytN|Ah[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF02Njd2NUSzJO69VQ>? NF7PZpNUSU6JRWK=
HLE cell NWqzc5BjT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MlnUTY5pcWKrdHnvckBw\iCqdX3hckBJVEViY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD13Lke3OFg6KM7:TR?= NX7MZYx6W0GQR1XS
T98G cell NG[zVodIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MoHtTY5pcWKrdHnvckBw\iCqdX3hckBVQTiJIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;NT63PVY{PSEQvF2= MnrlV2FPT0WU
HUTU-80 cell M2i2OGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NW\he4hvUW6qaXLpeIlwdiCxZjDoeY1idiCKVWTVMVgxKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PS56NEKyPEDPxE1? MmDuV2FPT0WU
NOS-1 cell NX\k[olzT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NITWWm9KdmirYnn0bY9vKG:oIHj1cYFvKE6RUz2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OU46PDd4NjFOwG0> NIPT[GtUSU6JRWK=
SW780 cell MX7Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NEXwc45KdmirYnn0bY9vKG:oIHj1cYFvKFOZN{iwJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OU46Pjl2OTFOwG0> M4PxUXNCVkeHUh?=
KYSE-180 cell MXLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NGnwb25KdmirYnn0bY9vKG:oIHj1cYFvKEu\U1WtNVgxKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PS57N{[1OEDPxE1? NILJTYpUSU6JRWK=
MDA-MB-361 cell MknQS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NUDLXWkxUW6qaXLpeIlwdiCxZjDoeY1idiCPRFGtUWIuOzZzIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;NT65PFY1PyEQvF2= MWXTRW5ITVJ?
SNU-C2B cell MmjlS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M1TtV2lvcGmkaYTpc44hd2ZiaIXtZY4hW06XLVOyRkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVYvODFzM{ig{txO MX7TRW5ITVJ?
NCI-H661 cell NXzZWndxT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NIjW[5BKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3IOlYyKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Pi5yNkm0JO69VQ>? MUfTRW5ITVJ?
OE33 cell NWD4W4VyT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M{PyfmlvcGmkaYTpc44hd2ZiaIXtZY4hV0V|MzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPU[uNVQ{QDlizszN MV3TRW5ITVJ?
TYK-nu cell M3m3PGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NEnZNFhKdmirYnn0bY9vKG:oIHj1cYFvKFS\Sz3ueUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVYvOjF6NkOg{txO MVTTRW5ITVJ?
COLO-792 cell MXHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MV;Jcohq[mm2aX;uJI9nKGi3bXHuJGNQVE9vN{myJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Ok4zPTJzOTFOwG0> MV;TRW5ITVJ?
HEL cell MVfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? Mn[yTY5pcWKrdHnvckBw\iCqdX3hckBJTUxiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD14LkK2O|Yh|ryP M3rBfnNCVkeHUh?=
D-566MG cell MXTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M{f2eWlvcGmkaYTpc44hd2ZiaIXtZY4hTC13Nk\NS{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVYvOzN2OUGg{txO NGfsWI5USU6JRWK=
U031 cell MojnS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MVnJcohq[mm2aX;uJI9nKGi3bXHuJHUxOzFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD14LkSxPFE3KM7:TR?= NIWzZYRUSU6JRWK=
COR-L23 cell M1G0TWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M33mR2lvcGmkaYTpc44hd2ZiaIXtZY4hS0:ULVyyN{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVYvPDN|NE[g{txO NGXVW2ZUSU6JRWK=
NCI-H2452 cell MVPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NFnIcYNKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3INlQ2OiClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTZwNUKyPFEh|ryP NG[1fYFUSU6JRWK=
BB65-RCC cell NGPCcm1Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= MXzJcohq[mm2aX;uJI9nKGi3bXHuJGJDPjVvUlPDJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Ok43PDV7IN88US=> NXLqSYV6W0GQR1XS
CAL-33 cell NWPhSVN3T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M1jiSmlvcGmkaYTpc44hd2ZiaIXtZY4hS0GOLUOzJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Ok43PTZ4NTFOwG0> M1jWZXNCVkeHUh?=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p53 / HDM2 / HDMX / p21 / Noxa / Puma ; 

PubMed: 20736344     


OCI-AML-3 and MOLM-13 cells were incubated with a range of concentrations of JNJ-26854165 for 18 hours.

ABCA1 / ABCG1 / NPC1 / NPC2 / HMGcoR ; 

PubMed: 23820125     


U266 and JeKo-1 cells were treated with JNJ-26854165 and cells harvested at the indicated time points.

MDM2 / p-MDM2 / p53 ; 

PubMed: 27999193     


K562 cells was harvested at 48 h after treatment with various JNJ-165 concentrations, and then nuclear and cytoplasmic extracts were prepared to check the levels of p53, MDM2 and p-MDM2 by Western blotting. Actin and LaminB were used as loading control respectively.

Bcr-abl / p-Bcr-abl / p-CrkL / STAT5 / p-STAT5 / STAT3 / p-STAT3 ; 

PubMed: 27999193     


CML cell lines were treated with JNJ-165 at the indicated doses for 48 h. Whole-cell lysates were extracted to assess the levels of BCR-ABL and phosphorylated (p)-BCR-ABL (Tyr177), and then were analyzed for BCR-ABL downstream signaling mediators p-CrkL (Try207), total Stat5, p-Stat5 (Tyr694), total Stat3, and p-Stat3 (Ser727) expression by Western blot analysis. The expression of β-actin was used as loading control. The data are representative of three determinations with identical results.

20736344 23820125 27999193
Growth inhibition assay
Cell viability; 

PubMed: 23820125     


MCL (B) and MM (C) cell lines were seeded in 96-well plates for viability analyses using WST-1 and treated with JNJ-26854165 for 72 hours. Results are expressed as the percentage of cell viability in relation to the vehicle-treated sample for each cell line, which was arbitrarily set at 100%

23820125
Immunofluorescence
p53; 

PubMed: 27999193     


Two-color fluorescence microscope analysis of antibody against p53 protein (green) and nuclei (DAPI staining, blue) showed nuclear accumulation of p53 in K562 cells with treatment of 1 μM JNJ-165, but not in control-treated cells after 48 h. Images were taken on a fluorescence microscopy (100×).

27999193
In vivo JNJ 26854165 leads to significant differences in EFS distribution in 17 of the 36 (47%) evaluable solid tumor xenografts and in 5 of 7 (71%) of the evaluable ALL xenografts using a dose of 20 mg/kg administered via oral gavage daily for 5 days, repeated for 6 weeks. [4]

Protocol

Cell Research:[1]
- Collapse
  • Cell lines: OCI-AML-3, MOLM-13, NB4 and U937 cells
  • Concentrations: 0-10 μM
  • Incubation Time: 72 hours
  • Method: Cell lines are maintained in RPMI 1640 medium containing 10% heat-inactivated fetal calf serum (FCS). OCI-AML-3, MOLM-13, NB4 and U937 cells are derived from acute myelogenous leukemia (AML) patients, K562 from a chronic myelogenous leukemia (CML) patient in blast crisis, and NALM-6, REH, P12-ICHIK
    (Only for Reference)
Animal Research:[4]
- Collapse
  • Animal Models: CB17SC scid-/- female mice.
  • Dosages: ≤20 mg/kg
  • Administration: Administered via p.o.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 66 mg/mL (200.96 mM)
Ethanol 2 mg/mL (6.08 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
1% DMSO+30% polyethylene glycol+1% Tween 80
For best results, use promptly after mixing.
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 328.41
Formula

C21H20N4

CAS No. 881202-45-5
Storage powder
in solvent
Synonyms N/A
Smiles C1=CC=C2C(=C1)C(=CN2)CCNC3=CC=C(C=C3)NC4=CC=NC=C4

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

p53 Signaling Pathway Map

Related p53 Products

Tags: buy JNJ-26854165 (Serdemetan) | JNJ-26854165 (Serdemetan) supplier | purchase JNJ-26854165 (Serdemetan) | JNJ-26854165 (Serdemetan) cost | JNJ-26854165 (Serdemetan) manufacturer | order JNJ-26854165 (Serdemetan) | JNJ-26854165 (Serdemetan) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID